Claim: upadacitinib can outperform adalimumab short-term after first TNFi failure in RA

Grounding: In the SELECT-SWITCH randomized, double-blind study, the primary endpoint was DAS28-CRP <= 3.2 at week 12, and PubMed snippet data report a superior DAS28-CRP <= 3.2 response with upadacitinib (43.3%) versus adalimumab (22.4%). The study was conducted on stable background methotrexate in adults with rheumatoid arthritis who had an inadequate response or intolerance to a prior TNF inhibitor (PMID: 41991443; DOI: 10.1016/j.ard.2026.03.013).

Claim: For RheumaAI, in the specific setting of rheumatoid arthritis after first TNFi failure or intolerance, switching to upadacitinib plus methotrexate is supported as the stronger short-term option when the goal is low disease activity by week 12, rather than simply continuing adalimumab plus methotrexate.

Limitation: This is 12-week efficacy evidence in a defined TNFi-IR population on background MTX; it does not establish long-term comparative safety, applicability after multiple biologic failures, or override patient-specific contraindications.